Eletriptan for acute migraine

Abstract

The editorial group responsible for this previously published document have withdrawn it from publication.

The clinical and financial impact of oral triptans - an updated meta-analysis

“…The data for eletriptan were derived from data listings within a Cochrane review 33 , as only one of the six studies described by the reviewers has been fully published to date 13 (see Discussion).…”

The clinical and financial impact of oral triptans - an updated meta-analysis

“…The data for eletriptan were derived from data listings within a Cochrane review 33 , as only one of the six studies described by the reviewers has been fully published to date 13 (see Discussion).…”

Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study

“…In contrast, previous trials [1][2][3][4][5] instructed the patients to wait until the pain was moderate or severe and subsequently low response rates for pain-free after 2 h, i.e., 28% [1] were found. In real life patients are also more likely to start treatment at the beginning of a migraine attack.…”

Headache

“…Both eletriptan 40 mg and 80 mg were superior to placebo [41]. Eletriptan 40 mg is a first-line treatment option in acute migraine attacks with a NNT of 2.9 (95% CI 2.6-3.3 [41] and eletriptan 80 mg (NNT 2.6, 95% CI 2.4-3.0) can be tried in especially severe migraine attacks. In one systematic review the efficacy parameter pain-free response at 2 hours was used [42] and sumatriptan 100 mg was superior to placebo with NNT of 5.1 (95% CI 3.9-7.1).…”

The clinical and financial impact of oral triptans - an updated meta-analysis

“…The data for eletriptan were derived from data listings within a Cochrane review 33 , as only one of the six studies described by the reviewers has been fully published to date 13 (see Discussion).…”

Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study

“…In contrast, previous trials [1][2][3][4][5] instructed the patients to wait until the pain was moderate or severe and subsequently low response rates for pain-free after 2 h, i.e., 28% [1] were found. In real life patients are also more likely to start treatment at the beginning of a migraine attack.…”

Headache

“…Both eletriptan 40 mg and 80 mg were superior to placebo [41]. Eletriptan 40 mg is a first-line treatment option in acute migraine attacks with a NNT of 2.9 (95% CI 2.6-3.3 [41] and eletriptan 80 mg (NNT 2.6, 95% CI 2.4-3.0) can be tried in especially severe migraine attacks. In one systematic review the efficacy parameter pain-free response at 2 hours was used [42] and sumatriptan 100 mg was superior to placebo with NNT of 5.1 (95% CI 3.9-7.1).…”

The clinical and financial impact of oral triptans - an updated meta-analysis

“…The data for eletriptan were derived from data listings within a Cochrane review 33 , as only one of the six studies described by the reviewers has been fully published to date 13 (see Discussion).…”

Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study

“…In contrast, previous trials [1][2][3][4][5] instructed the patients to wait until the pain was moderate or severe and subsequently low response rates for pain-free after 2 h, i.e., 28% [1] were found. In real life patients are also more likely to start treatment at the beginning of a migraine attack.…”

Headache

“…Both eletriptan 40 mg and 80 mg were superior to placebo [41]. Eletriptan 40 mg is a first-line treatment option in acute migraine attacks with a NNT of 2.9 (95% CI 2.6-3.3 [41] and eletriptan 80 mg (NNT 2.6, 95% CI 2.4-3.0) can be tried in especially severe migraine attacks. In one systematic review the efficacy parameter pain-free response at 2 hours was used [42] and sumatriptan 100 mg was superior to placebo with NNT of 5.1 (95% CI 3.9-7.1).…”